Biogen

Biogen

A biotechnology company with a focus on treatments for neurological and neurodegenerative diseases. It was founded in 1978 and has headquarters in Cambridge, Massachusetts.

Biogen is a United States-based company in the pharmaceutical industry that researches, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases. It has other locations world wide including Denmark and Switzerland. It has the stated goal of delivering therapies for its patients as well as investing in areas of highest return to deliver long-term value to its stockholders.

Products

The company manufactures therapies and medicines for diseases such as Parkinson's, Spinal Muscular Atrophy, and Multiple Sclerosis. It also researches solutions for other diseases such as Lupus, Epilepsy, and Schizophrenia. Biogen's drug aducanumab is under review by the Federal Drug Administration and has shown evidence of having the capability of reducing medical conditions that can cause Alzheimer's.

In March 2020, Biogen partnered with Vir to research and manufacture therapies for COVID-19. With the antibody development and manufacturing pact made between the two companies, Biogen would play the role of manufacturing and Vir has researched and developed the antibodies.

Timeline

People

Name
Role
LinkedIn

Alphonse Galdes, Ph.D.

Executive Vice President

Chirfi Guindo

Executive Vice President

Ginger Gregory, Ph.D.

Executive Vice President

Jeffrey Capello

Executive Vice President

Michel Vounatsos

CEO

Susan Alexander

Executive Vice President

Executive Vice President

Further reading

Title
Author
Link
Type
Date

Biogen signs on to manufacture clinical supplies for Vir's COVID-19 antibodies

Eric Sagonowsky

Web

March 12, 2020

Bloomberg - Are you a robot?

Bailey Lipschultz

Web

Documentaries, videos and podcasts

Title
Date
Link

Join Biogen's virtual reality experience at ECTRIMS in Stockholm

August 28, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
By MALCOLM RITTER, AP Science Writer
August 25, 2020
Houston Chronicle
NEW YORK (AP) - A meeting at a hotel in Boston last February may have ignited the spread of the pandemic virus to some 19,000 people in the area, a new study suggests. Health authorities had previously linked the meeting to more than 90 cases among people at the meeting and their contacts. But researchers found that a specific mutation in the virus from people associated with the meeting also showed up in hundreds of other cases, which allowed them to estimate the broader extent of the spread. It's "a pretty unsophisticated, back-of-the envelope calculation that we think gives us a sense of the scale," Bronwyn MacInnis of the Broad Institute of MIT and Harvard, senior author of the paper, said Tuesday. The research paper has been posted online but has not yet undergone peer review. The 19,000 figure does not appear in the paper because it was an informal calculation, MacInnis said. She and co-authors began their analysis by deciphering the genetic makeup of the new coronavirus that was recovered from people sampled mostly in the Boston area between January and May. Twenty-eight of those infected people were already among the 90 who had been linked to the gathering, an international meeting of executives of Biogen, a biotech company based in Cambridge, Massachusetts, in February. All of their samples were found to contain a tiny but distinctive genetic variant, which the the researchers then used as a marker to look for other cases related to the conference. That distinctive marker showed up in 246 samples that were not previously linked to the meeting and were recovered from residents in four nearby counties. Researchers used that result to extrapolate to the 19,000 figure. MacInnis said the marker did not make the virus particularly contagious or dangerous....
Amirah Al Idrus
July 8, 2020
FierceBiotech
It took a little longer than expected, but Biogen's done it--along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab, the Alzheimer's drug it resurrected just in time for Halloween. Aducanumab's fate will be a test of how far Stephen Hahn's FDA is willing to diverge from its established approval standards.
Arlene Weintraub
July 6, 2020
FierceBiotech
Biogen has formed a research pact with Harvard's Massachusetts Eye and Ear to develop a gene therapy for an inherited form of retinitis pigmentosa caused by mutations in the gene PRPF31. If it succeeds, it could help even more patients than the FDA-approved gene therapy for retinitis pigmentosa, Spark Therapeutics' Luxturna, the researchers believe.
Mark Terry
June 10, 2020
BioSpace
Biogen announced new data from the NURTURE trial of pre-symptomatic patients with spinal muscular atrophy (SMA).
Amirah Al Idrus
June 5, 2020
FierceBiotech
In December, Biogen delivered a "positive surprise" for its lupus candidate when all three doses of the drug outdid placebo at improving skin symptoms of the disease in a phase 2 trial. Now, the company is painting a fuller picture of the drug's effects, including safety data, in patients with lupus limited to their skin.
BioSpace
May 27, 2020
BioSpace
Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies
Joe Dwinell
April 18, 2020
Boston Herald
Biogen, home to the first super-spreading coronavirus outbreak in Massachusetts, is asking infected employees to give blood for a landmark COVID-19 study one researcher is calling part of a "Data Renaissance."
Joe Dwinell
March 16, 2020
Boston Herald
The biotech giant Biogen, now linked to 100 cases of coronavirus in Massachusetts, is kicking in $10 million to "support the global response" to the COVID-19 pandemic.
Joe Dwinell
March 10, 2020
Boston Herald
The coronavirus toll linked to a Biogen management meeting in Boston has now jumped to 32 people infected in Massachusetts -- with an investment bank in New York City alerting hundreds more about the viral risk.
Karen Weintraub
December 6, 2019
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Associated Press
October 22, 2019
Boston Herald
Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.
Matthew Herper
October 22, 2019
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Gina Kolata
October 22, 2019
www.nytimes.com
After declaring aducanumab a failure, the manufacturer now says the drug may help slow cognitive decline in certain patients. Some experts are skeptical.
Emma Court and Clarrie Feinstein
September 27, 2019
Business Insider
Since an analysis from Jefferies was released, three of the companies it tapped have said that they plan to go public.
Takashi Umekawa
March 21, 2019
U.S.
Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the experimental Alzheimer's drug aducanumab, marking the latest setback for an industry racing to develop treatments for the memory-robbing disease.
Reuters Editorial
March 21, 2019
U.S.
Biogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for an industry keen to develop treatments for the memory-robbing disease.
Fink Densford
March 13, 2019
MassDevice
The Medical Device Business Journal -- Medical Device News & Articles | MassDevice

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.